Literature DB >> 30589188

Breaking the Fourth Wall: Modulating Quaternary Associations for Protein Regulation and Drug Discovery.

Marcus J C Long1, Dziyana Hnedzko2, Bo Kyoung Kim3, Yimon Aye3.   

Abstract

Protein-protein interactions (PPIs) are an effective means to orchestrate intricate biological processes required to sustain life. Approximately 650 000 PPIs underlie the human interactome; thus underscoring its complexity and the manifold signaling outputs altered in response to changes in specific PPIs. This minireview illustrates the growing arsenal of PPI assemblies and offers insights into how these varied PPI regulatory modalities are relevant to customized drug discovery, with a focus on cancer. First, known and emerging PPIs and PPI-targeted drugs of both natural and synthetic origin are categorized. Building on these discussions, the merits of PPI-guided therapeutics over traditional drug design are discussed. Finally, a compare-and-contrast section for different PPI blockers, with gain-of-function PPI interventions, such as PROTACS, is provided.
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cancer; drug design; inhibitors; protein-protein interactions; quaternary associations

Mesh:

Substances:

Year:  2019        PMID: 30589188      PMCID: PMC6499692          DOI: 10.1002/cbic.201800716

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  130 in total

1.  Hot spot-based design of small-molecule inhibitors for protein-protein interactions.

Authors:  Wenxing Guo; John A Wisniewski; Haitao Ji
Journal:  Bioorg Med Chem Lett       Date:  2014-04-05       Impact factor: 2.823

2.  Blinatumomab for MRD+ B-ALL: the evidence strengthens.

Authors:  Patrick Brown
Journal:  Blood       Date:  2018-04-05       Impact factor: 22.113

3.  Arvinas, Pfizer Team Up on PROTACs.

Authors: 
Journal:  Cancer Discov       Date:  2018-02-16       Impact factor: 39.397

Review 4.  Recent advances in the therapeutic perspectives of Nutlin-3.

Authors:  Paola Secchiero; Raffaella Bosco; Claudio Celeghini; Giorgio Zauli
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 5.  Multiple functions of BCL-2 family proteins.

Authors:  J Marie Hardwick; Lucian Soane
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-02-01       Impact factor: 10.005

6.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

7.  The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity.

Authors:  Lara J Bou Malhab; Simon Descamps; Benedicte Delaval; Dimitris P Xirodimas
Journal:  Sci Rep       Date:  2016-11-30       Impact factor: 4.379

8.  Ube2V2 Is a Rosetta Stone Bridging Redox and Ubiquitin Codes, Coordinating DNA Damage Responses.

Authors:  Yi Zhao; Marcus J C Long; Yiran Wang; Sheng Zhang; Yimon Aye
Journal:  ACS Cent Sci       Date:  2018-01-17       Impact factor: 14.553

9.  Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.

Authors:  Michael Andreeff; Kevin R Kelly; Karen Yee; Sarit Assouline; Roger Strair; Leslie Popplewell; David Bowen; Giovanni Martinelli; Mark W Drummond; Paresh Vyas; Mark Kirschbaum; Swaminathan Padmanabhan Iyer; Vivian Ruvolo; Graciela M Nogueras González; Xuelin Huang; Gong Chen; Bradford Graves; Steven Blotner; Peter Bridge; Lori Jukofsky; Steve Middleton; Monica Reckner; Ruediger Rueger; Jianguo Zhi; Gwen Nichols; Kensuke Kojima
Journal:  Clin Cancer Res       Date:  2015-10-12       Impact factor: 12.531

10.  Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression.

Authors:  I Tala; R Chen; T Hu; E R Fitzpatrick; D A Williams; I P Whitehead
Journal:  Leukemia       Date:  2012-12-04       Impact factor: 11.528

View more
  1 in total

Review 1.  Wrangling Shape-Shifting Morpheeins to Tackle Disease and Approach Drug Discovery.

Authors:  Eileen K Jaffe
Journal:  Front Mol Biosci       Date:  2020-11-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.